Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Bolinger AM, Zangwill AB, Slattery JT, et al, “An Evaluation of Engraftment, Toxicity and Busulfan Concentration in Children Receiving Bone Marrow Transplantation for Leukemia or Genetic Disease,” Bone Marrow Transplant , 2000, 25(9):925-30. [PubMed 10800058 ] Heard BE and Cooke RA, “Busulphan Lung,” Thorax , 1968, 23(2):187-93. [PubMed 5240498 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Ozkaynak MF, Weinberg K, Kohn D, et al, “Hepatic Veno-Occlusive Disease Post-Bone Marrow Transplantation in Children Conditioned With Busulfan and Cyclophosphamide: Incidence, Risk Factors, and Clinical Outcome,” Bone Marrow Transplant , 1991, 7(6):467-74. [PubMed 1908340 ] Regazzi MB, Locatelli F, Buggia I, et al, “Disposition of High Dose Busulfan in Pediatric Patients Undergoing Bone Marrow Transplantation,” Clin Pharmacol Ther , 1993, 54(1):45-52. [PubMed 8330465 ] Vassal G, Gouyette A, Hartmann O, et al, “Pharmacokinetics of High-Dose Busulfan in Children,” Cancer Chemother Pharmacol , 1989, 24(6):386-90. [PubMed 2791192 ] Topic 13103 Version 38.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]